# A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

> clinical trial · VERIFIED · 2026-07-31

Status: ACTIVE_NOT_RECRUITING · Sponsor: Janssen Pharmaceutica N.V., Belgium · Condition: Arthritis, Psoriatic

- Company: Janssen Pharmaceutica N.V., Belgium
- Sector: Arthritis, Psoriatic
- Primary source: https://clinicaltrials.gov/study/NCT05049798

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.